MED10 and urothelial carcinoma: Using the mutual exclusivity test for MED10 and hsa-miR-590 in a pooled BLCA cohort (n = 786 patients, 806 samples) consisting of bladder cancer (MSK/TCGA, 2020 n = 476), bladder cancer (MSKCC, Eur Urol 2014 n = 109), bladder urothelial carcinoma (BGI, Nat Genet 2013 n = 99), bladder urothelial carcinoma (DFCI.MSKCC, Cancer Discov 2014 n = 50), and urothelial carcinoma (Cornell/Trento, Nat Gen 2016 n = 72), we confirmed the spatiotemporal association between the dyad (co-occurrence: log2 odds ratio >3, p = 0.02) (Figure 4A).